surveying postpartum nurses and obstetric providers about opioid use and then creating awareness and education around alternate medication options and the morbidity and mortality related to opioid misuse. During this phase, the existing postpartum pain management order set in the electronic health record was updated to promote use of opioid analgesia only when pain was not controlled by non-steroidal anti-inflammatory drugs. Also during this phase, department leaders presented inpatient opioid prescribing patterns and use at departmental meetings and providers were informed that provider-level data would be tracked going forward. The 2nd phase involved tracking opioid prescriptions at discharge. Department members were provided with their individual prescribing history for the previous month, as well as their rate relative to the monthly department average. This data was provided monthly for 3 consecutive months. RESULTS: In the 3 months before any interventions, 45% of women with an uncomplicated vaginal delivery received inpatient postpartum opioids, with an average number of doses consumed per patient of 7.6. During the post-intervention period, this rate decreased to 42% with an average of 5.5 doses per patient (p<0.01). During the 2nd phase of the project, the mean number of opioid doses prescribed at discharge per patient decreased from 11.7 in April 2018 to 6.7 in June 2018 (p<0.01). CONCLUSION: Education, performance feedback, and electronic health record order sets may be effective means to reduce unnecessary use of opioids, both inpatient and outpatient, after uncomplicated vaginal deliveries.
OBJECTIVE:
Accurate estimated blood loss (EBL) is a core tenet of postpartum hemorrhage (PPH) protocols. Quantitative blood loss (QBL) aims to overcome inaccuracies associated with visual EBL. We compared the accuracy of obstetric EBL for prediction of postpartum hemoglobin (Hgb) changes before and after adoption of a colorimetric QBL system (Triton, Gauss Surgical). STUDY DESIGN: Retrospective cohort of deliveries before ("pre-QBL," 8/2015-2/2017) and after ("post-QBL," 8/2018-3/2018) QBL adoption. Deliveries (3/2017 Deliveries (3/ -7/2017 were excluded during transition to QBL. Women met inclusion if they delivered at 20wks. All pre-QBL deliveries had physician EBL values. In the post-QBL phase, QBL was recorded as a separate value from physician EBL, but physicians were not blinded to the QBL value. The primary outcome was the difference between actual change in Hgb (predelivery HgbHgb 24hrs after delivery) and predicted change in Hgb (predelivery Hgb -predicted Hgb 24hrs after delivery). Differences closer to 0 were more accurate with -and + values reflecting over-and underestimation, respectively. Predicted Hgb values were calculated using EBL, maternal blood volume and predelivery Hgb. Analyses were stratified by mode of delivery and PPH (EBL>1000mL). A secondary analysis compared predicted change in Hgb using preintervention EBL values and post -intervention QBL values. Secondary outcomes included composite maternal morbidity (blood transfusion >2 units, embolization, hysterectomy, ICU, exploratory laparotomy, DIC, intubation, kidney injury, and death) and time from PPH to transfusion of blood products. Mean differences between pre-QBL and post-QBL were evaluated with two-sample Student t-tests. RESULTS: There were 9,101 deliveries; 2,753 were post-QBL. Physician EBL was less accurate for prediction of change in Hgb after implementation of QBL in deliveries without PPH (Table 1) . QBL values were more accurate than pre-intervention EBL values for prediction of Hgb change among cases of PPH (Table 2) . Although less accurate, EBL in cases of PPH was an overestimate of change in Hgb. There was no difference in maternal composite morbidity (9.8 vs 12.3%; p¼0.28) or median time to transfusion (17.0 vs 6.3 hours, p¼0.51) between pre-and post-QBL. CONCLUSION: QBL estimates were more accurate in the setting of PPH; however, QBL adoption did not improve morbidity or time to transfusion in our tertiary care center. Analysis of the utility of QBL in other settings is warranted. OBJECTIVE: Postpartum hemorrhage (PPH) is a leading cause of mortality and severe maternal morbidity (SMM). Research evidence demonstrates increasing risk for PPH, PPH severity, and associated morbidity. In response, the New York State Safe Motherhood Initiative (SMI) supported implementation of a bundle to improve management of PPH. We sought to assess (i) trends in PPH utilizing a novel multi-severity-level framework and (ii) hemorrhage-associated morbidity during PPH bundle implementation. STUDY DESIGN: This study analyzed PPH at a large, multi-site academic medical center from 7/2014 to 7/ 2017 during SMI hemorrhage bundle implementation. A novel framework was developed to track PPH risk factors, PPH severity, and indicators of PPH undertreatment. We analyzed changes in PPH levels over time using logistic regression accounting for PPH risk factors. Low fibrinogen levels were analyzed as a proxy for coagulopathy as an indicator for under-treatment. For these analyses, patients with no PPH were compared to patients with PPH based on severity within our framework.
RESULTS: Using a framework of PPH that includes 4 severity levels ( Figure 1A ), we found variation across time in incidence of PPH and treatment patterns ( Figure 1B ). PPH did not change over time according to ICD coding ("Coded PPH" in Figure 2A ). However, usage of uterotonics other than Pitocin increased significantly ("PPH1" in Figure 2A ), as did usage of Bakri Balloons and small volume (1-3 unit) red blood cell (RBC) transfusions ("PPH3" in Figure 2A ). Hysterectomy and/or RBC transfusion 4 units did not increase significantly ("PPH4" in Figure 2A ). Cases with fibrinogen<¼200, an under-treatment indicator, did not increase significantly over time (p¼0.10 in logistic regression) and there were no PPH related maternal mortalities during hospitalization in the study period. CONCLUSION: Based on trends in uterotonic use, transfusion <4 units RBCs and Bakri use, PPH incidence and risk appeared to increase. This risk was not captured in routine billing data. Hemorrhage bundles call for early recognition of PPH with stagebased response including uterotonic medication, tamponade, and transfusion. Clinical uptake of these recommendations occurred over the study period. Despite increases in PPH risk and severity, key measures of SMM, including hysterectomy and coagulopathy, did not increase.
